(Shared Conference with World Preclinical Congress and IO Pharma Congress)

Cambridge Healthtech Institute’s 6th Annual

Cancer Immunotherapy Models

Predictable Cancer IO Models for Improved Translation

June 19-20, 2019


The demand for more predictive and robust preclinical models to minimize translational failure for oncology research, especially immune-oncology research, is at an all-time high. The need for leveraging phenotypic features of models and stimulating the response of immune system adds to the complexity of preclinical models and their applications. Special emphasis is currently being placed on development and preclinical assessment of combination therapies and their rational preclinical design. Cambridge Healthtech Institute’s 6th Annual Cancer Immunotherapy Models is designed to discuss cutting-edge, complex, immunocompetent models for cancer immunotherapy research as well as to present case studies of their successful applications.

TUMOR MODELS FOR CANCER IMMUNOTHERAPY

Human Tumor Organoids as a Novel Model for Drug Discovery and Screening

Janica Wong, PhD, Senior Scientist, Translational Pathology, Merck Research Labs

Implantable Pre-Metastatic Niches for the Study of the Microenvironmental Regulation of Disseminated Tumor Cells

Jungwoo Lee, PhD, Assistant Professor, Chemical Engineering Department & Institute for Applied Life Sciences, University of Massachusetts - Amherst

MICROFLUIDIC TECHNOLOGIES TO SCREEN FOR PATIENT SPECIFIC IMMUNOTHERAPIES

Ex vivo Profiling of Response to PD-1 Blockade Using Organotypic Tumor Spheroids

Elena Ivanova, PhD, Senior Scientist, Medical Oncology, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute

Cancer Models: Immune Checkpoint Blockade Therapies and Metastatic Disease

Roger D. Kamm, PhD, Green Distinguished Professor of Mechanical and Biological Engineering, Departments of Mechanical Engineering and Biological Engineering, Massachusetts Institute of Technology

TANK-Binding Kinase 1 (TBK1) as a Cancer Immunotherapy Target

Russell W. Jenkins, MD, PhD, Assistant Professor, Department of Medicine, Center for Cancer Research, Massachusetts General Hospital

HTS FOR ONCOLOGY

APDX/Organoid Biobank of Advanced Prostate Cancer for Disease Modeling and Therapeutic Screening

Kathleen Kelly, PhD, Lab Chief, Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute

High Throughput Screening for Spheroids 

Louis Scampavia, PhD, Senior Scientific Director, Molecular Medicine Department, Scripps Research, Florida Campus

RECAPITULATING THE IN VIVO TUMOR MICROENVIRONMENT

Human Patient-Derived Tumor Organoids: Ex vivo Chemosensitivy Screening and Immune-Enhancing for Immunotherapy Responsiveness Screening

Aleksander Skardal, PhD, Assistant Professor, Wake Forest Institute for Regenerative Medicine

 


For more details on the conference, please contact:
Mana Chandhok
Conference Producer
Cambridge Healthtech Institute
Phone: 781-972-1350
Email: mchandhok@healthtech.com

For partnering and sponsorship information, please contact:


Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com